Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSR | P00390 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 13/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 7/20 | 0.45 |
| ▸ | DPP4 | P27487 | 5/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 5/20 | 0.43 |
| ▸ | FAP | Q12884 | 1/20 | 0.43 |
| ▸ | TPSAB1 | Q15661 | 3/20 | 0.43 |
| ▸ | TPSD1 | Q9BZJ3 | 3/20 | 0.43 |
| ▸ | TPSG1 | Q9NRR2 | 3/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.40 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.40 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7782967 | 0.98 | GSR (0.46) | GSRDPP7DPP8DPP4DPP9 | |
| SCHEMBL7782965 | 0.98 | GSR (0.46) | GSRDPP7DPP8DPP4DPP9 | |
| Hydrochloric Acid SCHEMBL11524970 | 0.97 | GSR (0.44) | GSRDPP7DPP8DPP4DPP9 | |
| Hydrochloric Acid SCHEMBL11524966 | 0.97 | GSR (0.44) | GSRDPP7DPP8DPP4DPP9 | |
| SCHEMBL28614001 | 0.93 | MAPK13 (0.40) | GSRDPP7DPP8DPP4DPP9 | |
| SCHEMBL23454411 | 0.88 | DPP7 (0.44) | GSRDPP7DPP8DPP4DPP9 | |
| SCHEMBL10611587 | 0.88 | GSR (0.42) | GSRDPP7DPP8DPP4DPP9 | |
| SCHEMBL10611597 | 0.88 | GSR (0.42) | GSRDPP7DPP8DPP4DPP9 | |
| SCHEMBL15543405 | 0.85 | MAPK13 (0.39) | DPP7DPP4TPSAB1TPSD1TPSG1 | |
| SCHEMBL15543404 | 0.85 | MAPK13 (0.39) | DPP7DPP8DPP4TPSAB1TPSD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2013175-B9 | p38 MAP KINASE INHIBITORS | MACROPHAGE PHARMA LTD (GB) | 2020-11-11 | — | — | EP | disclosed |
| EP-2013175-B1 | p38 MAP KINASE INHIBITORS | CHROMA THERAPEUTICS LTD (GB) | 2016-11-09 | — | — | EP | disclosed |
| US-8044211-B2 | P38 MAP kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-10-25 | — | — | US | disclosed |
| US-20090099185-A1 | P38 Map Kinase Inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099185-A1 | P38 Map Kinase Inhibitors | MAPK1, CNKSR1, MAPK3 | GSR 1509/4885DPP7 3110/4885DPP8 3508/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.